MedTrace Logo

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

NCT04944069 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2021-06-29

No results posted yet for this study

Summary

A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.

Conditions

  • NSCLC
  • Leptomeningeal Metastasis
  • EGFR Activating Mutation

Interventions

DRUG

Almonertinib

110 mg oral once daily

DRUG

Bevacizumab

15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Second Affiliated Hospital of Nanchang University

    lead OTHER

Principal Investigators

  • Liu Anwen, PhD · Second Affiliated Hospital of Nanchang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2024-03-31
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04944069 on ClinicalTrials.gov